8-K: ALX Oncology Announces Leadership Changes

ALX Oncology Holdings Inc. has appointed Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel, with Corey Goodman, Ph.D. stepping down as Chairman.

Summary

• ALX Oncology Holdings Inc. announced leadership changes effective June 29, 2026.
• Corey Goodman, Ph.D. resigned as Chairman and a member of the Board for personal reasons.
• Scott Garland, an independent director, has been appointed as the new Chairman of the Board.
• Michael Listgarten has been appointed as the new General Counsel.
• The company also updated the composition of its Board committees: Audit Committee, Compensation Committee, and Corporate Governance and Nominating Committee.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, reflecting a planned leadership transition with experienced individuals stepping into key roles to support the company's growth strategy.

Positives

• Scott Garland, with over 30 years of biopharmaceutical industry experience, brings extensive commercial and operational expertise to his role as Chairman.
• Michael Listgarten, with over 30 years of legal experience in the biopharmaceutical sector, is expected to provide crucial guidance on complex transactions, governance, and public company matters.
• The transition is described as seamless, with continued momentum for the company.
• Corey Goodman's contributions to the company's scientific direction and development of evorpacept and ALX2004 are acknowledged.
• The company is advancing its pipeline with evorpacept in late-stage development and ALX2004 in Phase 1 trials.

Negatives

• The departure of a co-founder and long-time Chairman, Corey Goodman, Ph.D., may be viewed as a loss of foundational leadership, despite his stated reasons for resignation.

Risks

• The company faces risks and uncertainties related to the development and commercialization of its product candidates, evorpacept and ALX2004.
• Future results of operations, financial position, business strategy, and regulatory approvals are subject to known and unknown risks and uncertainties.
• The company's ability to successfully advance its pipeline and achieve critical milestones is subject to inherent risks in clinical development and regulatory processes.

Future Outlook

The company is focused on advancing its pipeline, including evorpacept into registration studies and progressing ALX2004, while deepening strategic partnerships and executing its long-term growth strategy. The new leadership is expected to ensure continued momentum and deliver long-term value.

Management Comments

• "It has been a privilege to serve as Chairman since co-founding the Company. I am incredibly proud of the progress we have made, particularly advancing evorpacept into late-stage development and progressing ALX2004, both of which have potential of addressing multiple high-need oncology patient populations. Scott is a highly respected leader with a strong track record and I am confident that, under his guidance, the Company will continue to execute at this pivotal stage of growth and deliver long-term value to our stockholders."
• "Coreys contributions to ALX Oncology are immeasurable. He helped define our scientific direction and led with unwavering commitment through every stage of the Companys development. The progress we have made with evorpacept and ALX2004 would not exist without him, and Im deeply grateful for everything Corey has given to this Company and to the patients we serve. I am equally pleased to welcome Scott as Chairman of our Board. Scott has been an invaluable board member and a trusted partner to our management team. His guidance will be critical as we advance our pipeline and approach critical milestones for both of our programs."
• "Michael is a highly accomplished legal leader with a proven track record of guiding biopharmaceutical companies through critical inflection points. His deep domain expertise across complex transactions, governance, and public company matters will be crucial as we advance evorpacept into registration studies, progress ALX2004, deepen our strategic partnerships, and continue executing on our long-term growth strategy."

Industry Context

StockSavvy.ai notes that leadership transitions are common in the dynamic biotechnology sector, especially for clinical-stage companies navigating complex development and regulatory pathways. The appointment of experienced executives like Scott Garland and Michael Listgarten signals a focus on strategic execution and governance as ALX Oncology advances its promising oncology pipeline.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of experienced leaders is intended to drive long-term value and continued execution of the company's growth strategy.
• Employees: The leadership changes and continued focus on pipeline advancement provide stability and direction.
• Patients: The ongoing development of novel therapies like evorpacept and ALX2004 aims to address unmet needs in oncology.

Next Steps

• Continue advancing evorpacept into registration studies.
• Progress ALX2004 development.
• Deepen strategic partnerships.
• Execute on the company's long-term growth strategy.

Key Dates

Recommendation

The filing details routine leadership changes and committee updates, without significant new financial data or strategic shifts that would warrant a change in investment recommendation. The company continues to advance its pipeline, which is a positive, but the core investment thesis remains unchanged by this announcement.

Keywords

ALX Oncology, Board of Directors, Chairman, General Counsel, Leadership Change, Biotechnology, Oncology, Clinical Stage, Evorpacept, ALX2004, SEC Filing, Form 8-K